parlodel
| Product dosage: 1.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.50 | $50.06 (0%) | 🛒 Add to cart |
| 30 | $2.10 | $75.08 $63.07 (16%) | 🛒 Add to cart |
| 60 | $1.70 | $150.17 $102.12 (32%) | 🛒 Add to cart |
| 90 | $1.50 | $225.25 $135.15 (40%) | 🛒 Add to cart |
| 120 | $1.40 | $300.34 $168.19 (44%) | 🛒 Add to cart |
| 180 | $1.30 | $450.51 $234.26 (48%) | 🛒 Add to cart |
| 270 | $1.25 | $675.76 $337.38 (50%) | 🛒 Add to cart |
| 360 | $1.20
Best per pill | $901.02 $432.49 (52%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.70 | $54.06 (0%) | 🛒 Add to cart |
| 30 | $2.37 | $81.09 $71.08 (12%) | 🛒 Add to cart |
| 60 | $1.82 | $162.18 $109.12 (33%) | 🛒 Add to cart |
| 90 | $1.58 | $243.27 $142.16 (42%) | 🛒 Add to cart |
| 120 | $1.54 | $324.37 $184.21 (43%) | 🛒 Add to cart |
| 180 | $1.52 | $486.55 $273.31 (44%) | 🛒 Add to cart |
| 270 | $1.40 | $729.82 $378.43 (48%) | 🛒 Add to cart |
| 360 | $1.30
Best per pill | $973.10 $468.53 (52%) | 🛒 Add to cart |
Synonyms | |||
Bromocriptine mesylate, marketed under the brand name Parlodel, represents one of the older dopamine agonists in our neurological and endocrine toolkit. It’s fascinating how this ergot-derived compound has maintained clinical relevance despite newer agents entering the market. The drug’s unique receptor profile—particularly its D2 dopamine receptor agonism with some D1 antagonism—creates a pharmacological signature that still finds specific niches where newer non-ergot derivatives might not suffice.
Parlodel: Dopamine Agonist Therapy for Hyperprolactinemia and Parkinson’s Disease - Evidence-Based Review
1. Introduction: What is Parlodel? Its Role in Modern Medicine
Parlodel, the brand name for bromocriptine mesylate, belongs to the ergot alkaloid class of dopamine receptor agonists. Initially developed in the 1960s and approved by the FDA in 1978, this medication has served as a cornerstone in managing hyperprolactinemic disorders, Parkinson’s disease, and acromegaly. What many younger clinicians don’t realize is that Parlodel was actually one of the first dopamine agonists to demonstrate that we could manipulate pituitary function through neurotransmitter modulation rather than resorting directly to surgery.
The drug’s significance extends beyond its approved indications—we’ve used it off-label for neuroleptic malignant syndrome, type 2 diabetes, and even peripartum cardiomyopathy. Its versatility stems from bromocriptine’s ability to activate dopamine D2 receptors while partially blocking D1 receptors, creating a unique pharmacological profile that differs from newer non-ergot agonists like pramipexole or ropinirole.
2. Key Components and Bioavailability Parlodel
Bromocriptine mesylate, the active component in Parlodel, is a semisynthetic ergot alkaloid derived from claviceps purpurea. The molecular structure includes a peptide-like ergoline framework that allows both dopamine agonist and mild antagonist properties depending on the receptor subtype. The mesylate salt formulation was specifically developed to enhance oral bioavailability, though honestly, the absorption is still pretty variable between patients—anywhere from 28% to 50% depending on gastric pH and motility.
The conventional tablets require careful timing with food to minimize the notorious gastrointestinal side effects, though this also reduces peak concentrations by about 30-40%. We’ve found that starting with the lowest possible dose and gradual titration remains crucial, something I learned the hard way early in my career when I rushed the titration and had patients calling with unbearable nausea.
The quick-release formulation means multiple daily dosing is often necessary, which creates adherence challenges compared to newer once-daily formulations. The pharmacokinetics show extensive first-pass metabolism primarily via CYP3A4 in the liver, with a half-life of approximately 3-5 hours, though the pharmacological effects persist longer due to active metabolites.
3. Mechanism of Action Parlodel: Scientific Substantiation
Bromocriptine’s mechanism is more nuanced than simply “dopamine agonist.” The drug acts as a potent D2 receptor agonist while functioning as a partial D1 receptor antagonist. This dual action creates a different clinical profile compared to non-selective agonists. In hyperprolactinemia, Parlodel directly stimulates dopamine D2 receptors on pituitary lactotroph cells, inhibiting prolactin synthesis and secretion through adenylate cyclase suppression.
For Parkinson’s disease, the drug activates striatal D2 receptors, helping restore the dopamine-acetylcholine balance in the nigrostriatal pathway. What’s particularly interesting is that unlike levodopa, bromocriptine doesn’t require conversion to active metabolites—it acts directly on postsynaptic receptors, which theoretically might reduce oxidative stress from dopamine metabolism.
In acromegaly, the mechanism involves D2 receptor activation on somatotroph cells, reducing growth hormone secretion, though the response is more variable than with prolactinomas. We’ve observed that patients with denser D2 receptor expression typically show better GH suppression.
4. Indications for Use: What is Parlodel Effective For?
Parlodel for Hyperprolactinemia
This remains the strongest indication, with response rates exceeding 80% for microprolactinomas and 60-70% for macroprolactinomas. The drug not only normalizes prolactin levels but often produces tumor shrinkage—I’ve seen macroprolactinomas reduce by 50% or more within 6-12 months. For fertility concerns, Parlodel reliably restores ovulatory cycles in women and improves hypogonadism in men.
Parlodel for Parkinson’s Disease
While now considered second-line after non-ergot derivatives, bromocriptine still has utility in certain Parkinson’s patients, particularly those developing early motor complications on levodopa. The evidence supports reduced “off” time when added to levodopa regimens, though the effect size is modest compared to newer agents.
Parlodel for Acromegaly
As monotherapy, it normalizes IGF-1 in only about 10% of acromegaly patients, but as adjunctive therapy after surgery or with somatostatin analogs, the response improves significantly. The patients who do respond often have mixed GH-prolactin secreting adenomas.
Parlodel for Type 2 Diabetes
The quick-release formulation gained FDA approval for type 2 diabetes based on its effects on central sympathetic tone and hepatic glucose production. The mechanism appears unrelated to dopamine effects on prolactin—instead involving circadian neurotransmitter resetting that improves insulin sensitivity.
5. Instructions for Use: Dosage and Course of Administration
The key with Parlodel is slow, gradual titration to minimize side effects. For hyperprolactinemia, we typically start with 1.25 mg at bedtime with food, increasing by 1.25-2.5 mg every 3-7 days as tolerated. Most patients achieve prolactin normalization at 2.5-7.5 mg daily, though I’ve had some macroprolactinoma patients requiring 15-20 mg daily.
| Indication | Starting Dose | Maintenance Range | Administration |
|---|---|---|---|
| Hyperprolactinemia | 1.25 mg HS | 2.5-7.5 mg daily | With food, bedtime dose |
| Parkinson’s disease | 1.25 mg BID | 10-40 mg daily | With meals, divided doses |
| Acromegaly | 1.25 mg HS | 10-30 mg daily | With food, divided doses |
| Type 2 diabetes | 0.8 mg QAM | 1.6-4.8 mg daily | Within 2 hours of waking |
For Parkinson’s, we typically add Parlodel to existing levodopa regimens when motor complications emerge, starting at 1.25 mg twice daily and increasing gradually. Many patients can eventually reduce their levodopa dose by 10-30% when bromocriptine is optimized.
6. Contraindications and Drug Interactions Parlodel
Absolute contraindications include hypersensitivity to ergot alkaloids, uncontrolled hypertension, and toxemia of pregnancy. The drug should be avoided in severe peripheral vascular disease, coronary artery disease, and hepatic impairment.
The most concerning interactions involve other medications metabolized by CYP3A4. Macrolide antibiotics, azole antifungals, and protease inhibitors can significantly increase bromocriptine levels—I once managed a case where clarithromycin sent a patient’s bromocriptine levels threefold higher, resulting in profound hypotension requiring hospitalization.
Dopamine antagonists like metoclopramide, antipsychotics, and some antiemetics directly oppose Parlodel’s therapeutic effects. The combination with sumatriptan or other ergot derivatives increases ergotism risk. Hypertension medications may require adjustment as bromocriptine can cause hypotension, particularly during initiation.
7. Clinical Studies and Evidence Base Parlodel
The evidence for hyperprolactinemia management remains robust despite the drug’s age. A 2018 systematic review in Pituitary analyzed 27 studies involving over 1,200 patients, finding prolactin normalization in 82% of microprolactinoma patients and 67% of macroprolactinoma cases. Tumor shrinkage occurred in approximately 60% of macroadenomas, with average volume reduction of 52%.
For Parkinson’s disease, the older PD MED study found bromocriptine provided similar quality-of-life benefits to levodopa initially but with fewer motor complications—though the trade-off was more frequent non-motor side effects. The 5-year follow-up data suggested that starting with dopamine agonists like bromocriptine delayed dyskinesia onset by approximately 2 years compared to levodopa initiation.
The type 2 diabetes approval was based on the Cycloset Safety Trial, which demonstrated 0.7% HbA1c reduction with bromocriptine-QR versus 0.1% with placebo, without weight gain or hypoglycemia risk escalation.
8. Comparing Parlodel with Similar Products and Choosing a Quality Product
Compared to cabergoline, Parlodel has shorter duration of action requiring multiple daily doses, but also less concern about cardiac valve fibrosis—the ergot structure differences matter clinically. Versus non-ergot agonists like pramipexole, bromocriptine has more gastrointestinal side effects but potentially less impulse control disorder risk.
When choosing between dopamine agonists, consider:
- Hyperprolactinemia: Cabergoline generally preferred for potency and dosing convenience, but Parlodel remains effective and costs less
- Parkinson’s: Non-ergot agonists typically first-line due to better tolerability
- Cost factors: Parlodel often significantly less expensive, though insurance coverage varies
- Comorbidities: Avoid ergot derivatives in significant cardiac or peripheral vascular disease
Generic bromocriptine maintains bioequivalence to branded Parlodel, with multiple manufacturers ensuring supply consistency.
9. Frequently Asked Questions (FAQ) about Parlodel
How long does Parlodel take to lower prolactin levels?
Most patients see significant reduction within 2-3 weeks, though normalization may take 4-8 weeks depending on baseline elevation. Macroprolactinomas sometimes require 3-6 months for full effect.
Can Parlodel be taken during pregnancy?
We typically discontinue once pregnancy is confirmed in prolactinoma patients, though macroprolactinomas may require continued treatment with careful monitoring. The safety data is reasonably reassuring, with no major teratogenicity signal.
What monitoring is required during Parlodel therapy?
Baseline and periodic echocardiograms aren’t necessary like with cabergoline, but we check prolactin levels monthly during titration, liver enzymes quarterly, and blood pressure regularly during initiation.
Why is Parlodel taken at night?
The bedtime dose helps minimize initial side effects while leveraging the drug’s prolactin-lowering effects during the nocturnal prolactin surge.
Can Parlodel cause psychiatric side effects?
Yes, hallucinations, confusion, and impulse control disorders can occur, though less frequently than with some newer agonists. We monitor closely in elderly patients and those with psychiatric history.
10. Conclusion: Validity of Parlodel Use in Clinical Practice
Despite being overshadowed by newer agents, Parlodel maintains important therapeutic niches where its specific receptor profile, cost-effectiveness, and extensive safety database offer advantages. The drug requires careful patient selection and methodical titration but can produce excellent outcomes in hyperprolactinemia, selected Parkinson’s cases, and adjunctive acromegaly management.
I remember my first complex Parlodel case back in 2005—Sarah, a 32-year-old teacher with a 15mm prolactinoma who’d failed cabergoline due to intolerable dizziness. We switched to bromocriptine with the slowest titration I’d ever attempted: 0.625 mg every third day initially. My senior partner thought I was being overly cautious, but within three months, her prolactin dropped from 480 to 18 ng/mL, and the MRI showed 40% tumor reduction without the side effects that plagued her on cabergoline.
Then there was Mr. Henderson, 74 with advanced Parkinson’s and severe dyskinesias. We’d tried everything—amantadine, clozapine, even Duodopa. As a last resort, I added bromocriptine to his regimen despite concerns about his age. The first two weeks were rough with nausea, but once we got to 15mg daily, his “off” time decreased from 5 to 2 hours daily. His wife told me it was the first time in years he’d been able to finish a restaurant meal without embarrassing dyskinesias.
The development wasn’t straightforward though—our clinic initially resisted using Parlodel for diabetes, concerned about off-label prescribing. I had to present data from three randomized trials before we developed a protocol. Even then, our first type 2 diabetes patient on bromocriptine-QR stopped after two days due to nausea. We learned to use even lower starting doses than recommended—sometimes quartering the 0.8mg tablets.
What surprised me most was discovering that about 15% of our “bromocriptine failures” were actually administration errors—patients taking it on empty stomachs despite repeated instructions. Once we implemented teach-back methods and scheduled doses around specific meals, success rates improved dramatically.
Follow-up with Sarah showed maintained prolactin normalization for eight years now, though she eventually needed a slight dose increase after her second pregnancy. Mr. Henderson maintained benefit for three years before his Parkinson’s progression required additional interventions. The diabetes patients have been more mixed—about 40% achieve sustained HbA1c reductions, but those who respond often maintain benefits long-term with minimal side effects after the initial adaptation period.
Just last month, Sarah sent a photo of her family—two children she wouldn’t have had without successful prolactinoma management. “That stubborn old drug you believed in gave me this,” she wrote. Sometimes the older tools, when applied thoughtfully, still produce the most meaningful outcomes.